Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Prospective Non-Interventional Study to Describe the Effectiveness and Safety of Venetoclax as a First-Line Treatment in Acute Myeloid Leukemia (AML) Patients Who Are Ineligible to Intensive Chemotherapy in Routine Clinical Practice in Greece

NCT05317494 is registered in ClinicalTrials.gov with AbbVie as lead sponsor.

NCT NCT05317494
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT05317494 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Prospective Non-Interventional Study to Describe the Effectiveness and Safety of Venetoclax as a First-Line Treatment in Acute Myeloid Leukemia (AML) Patients Who Are Ineligible to Intensive Chemotherapy in Routine Clinical Practice in Greece
Lead sponsor
AbbVie
Phase
Observational
Overall status
Completed
Start date
May 26, 2022
Completion date
May 29, 2026
Enrollment
106 (actual)
Sites
13

Conditions

As the registry lists them; a condition with its own page is linked.

acute myeloid leukemia